Common Contracts
2 similar Exclusive License Agreement contracts by IVERIC Bio, Inc.
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®Exclusive License Agreement • July 5th, 2022 • IVERIC Bio, Inc. • Pharmaceutical preparations
Parsippany, N.J. and Turku, Finland – July 5, 2022 – IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD). These technologies potentially could address patients being treated for geographic atrophy (GA) and intermediate AMD.
Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®Exclusive License Agreement • July 5th, 2022
PARSIPPANY, N.J. & TURKU, Finland--(BUSINESS WIRE)--Jul. 5, 2022-- IVERIC bio, Inc. (Nasdaq: ISEE) and DelSiTech Ltd, announced today an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura® (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. As part of Iveric Bio’s lifecycle expansion plan for Zimura, the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD). These technologies potentially could address patients being treated for geographic atrophy (GA) and intermediate AMD.
